
Oncology NEWS International
- Oncology NEWS International Vol 17 No 4
- Volume 17
- Issue 4
Gardasil supplemental application gets priority review designation
Merck & Co., Inc.’s supplemental Biologics License Application for use of Gardasil in women aged 27 through 45 has been accepted by the FDA and designated for priority review.
WHITEHOUSE STATION, New Jersey-Merck & Co., Inc.’s supplemental Biologics License Application for use of Gardasil in women aged 27 through 45 has been accepted by the FDA and designated for priority review. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant] is currently indicated for girls and women age 9 through 26 for the prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by HPV types 6, 11, 16, and 18.
Articles in this issue
almost 18 years ago
Proton therapy training offeredalmost 18 years ago
Editor of Blood reviews a very bloody moviealmost 18 years ago
Artists take note: Oncology on Canvas accepting entriesalmost 18 years ago
PET affects treatment in over one-third of cancer casesalmost 18 years ago
Expanded use of Axxent approvedalmost 18 years ago
Optical tomo/US monitors adjuvant chemo responsealmost 18 years ago
GIST patients resistant to imatinib/sunitinib respond to sorafenibalmost 18 years ago
Sunitinib plus a taxane active in advanced breast canceralmost 18 years ago
Stanford V yields excellent outcomes in bulky, advanced HLalmost 18 years ago
Monica Morrow joins Memorial Sloan-Kettering Cancer CenterNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































